Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.59 |
| ▸ | TUBB | P07437 | 2/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055888 | 0.87 | IKBKB (0.77) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL7052936 | 0.82 | IKBKB (0.69) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL7057054 | 0.82 | MAPT (0.69) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL1382279 | 0.79 | IKBKB (1.00) | IKBKBMAPTALDH1A1HDAC6CYP1A2 | |
| SCHEMBL612267 | 0.79 | CDC7 (1.00) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL6612593 | 0.78 | IKBKB (0.76) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL1847243 | 0.78 | IKBKB (1.00) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL5898679 | 0.77 | IKBKB (0.64) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL6608113 | 0.77 | IKBKB (0.73) | IKBKBMAPTALDH1A1HDAC6CDC7 | |
| SCHEMBL4097325 | 0.75 | IKBKB (1.00) | IKBKBMAPTALDH1A1HDAC6CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263669-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | UNIV TSINGHUA (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| US-20240408145-A1 | Gene Therapy | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-12-12 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| EP-4419543-A1 | GENE THERAPY | Ospedale San Raffaele S.r.l. (IT) | 2024-08-28 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| EP-4394030-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | Tsinghua University (CN) | 2024-07-03 | — | — | EP | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| WO-2023066735-A1 | GENE THERAPY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-04-27 | — | — | WO | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | claimed |
| US-20040192943-A1 | Nf-kappab inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1444010-A2 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | claimed |
| WO-2003037886-A2 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-05-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192943-A1 | Nf-kappab inhibitors | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885MAPT 1500/4885ALDH1A1 3660/4885 |
| US-20240408145-A1 | Gene Therapy | MCL1, DNASE1L3, CDKN1A | IKBKB 334/4885MAPT 3015/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.